Generalised anxiety disorder

On this page

Quick Overview

Generalised Anxiety Disorder (GAD) is persistent, excessive worry about multiple domains (≥6 months) causing significant functional impairment. Affects 4-5% of UK adults, twice as common in women. NICE CG113 emphasises stepped care starting with low-intensity interventions before pharmacotherapy, optimising resource allocation while maintaining clinical effectiveness.

Core Facts & Concepts

Diagnostic Criteria (ICD-10/DSM-5)

  • Duration: Anxiety/worry present most days for ≥6 months
  • Multiple domains: Worry across ≥2 life circumstances (work, health, finances, relationships)
  • Uncontrollable: Patient finds worry difficult to control
  • Physical symptoms (≥3 required): Restlessness, fatigue, concentration difficulty, irritability, muscle tension, sleep disturbance

GAD-7 Assessment Tool Interpretation

  • Score 0-4: Minimal anxiety
  • Score 5-9: Mild anxiety (consider low-intensity intervention)
  • Score 10-14: Moderate anxiety (consider high-intensity intervention)
  • Score 15-21: Severe anxiety (refer specialist services if needed)

Figure 1: Clinical photograph showing patient with visible muscle tension and restless posture characteristic of GAD presentation

Key Epidemiology & Risk Factors

  • Peak onset: 35-54 years
  • Comorbidity: 50-90% have coexisting depression
  • Chronic course: 50% remain symptomatic at 5 years without treatment
  • Risk factors: Female sex, chronic physical illness, substance misuse, childhood adversity

Stepped Care Model (NICE CG113)

StepInterventionProvider
Step 1Identification, psychoeducation, active monitoringPrimary care
Step 2Low-intensity psychological intervention (guided self-help, psychoeducation groups)IAPT/primary care
Step 3High-intensity intervention (CBT) OR drug treatmentPrimary care ± mental health
Step 4Specialist assessment, complex drug/psychological treatmentSecondary care

Problem-Solving Approach

Clinical Assessment Pathway

  1. Screen with GAD-7 in primary care (routine in patients presenting with anxiety symptoms)
  2. Assess functional impairment: Work, relationships, daily activities
  3. Rule out physical causes: Hyperthyroidism, cardiac arrhythmias, substance withdrawal, caffeine excess
  4. Evaluate comorbidities: Depression (PHQ-9), panic disorder, PTSD, substance misuse
  5. Risk assessment: Self-harm, suicide risk (especially with comorbid depression)

Figure 2: GAD-7 questionnaire form showing seven-item scale with scoring system

Pharmacotherapy Selection (NICE CG113)

First-line SSRI:

  • Sertraline preferred (evidence base, cost-effectiveness)
  • Alternative SSRIs: Escitalopram, paroxetine
  • Start low dose, review at 2-4 weeks, therapeutic trial 12 weeks
  • Warn: Increased anxiety first 2 weeks, discontinuation symptoms

Second-line SNRI:

  • Venlafaxine XL or duloxetine if SSRI ineffective/not tolerated
  • Venlafaxine requires monitoring: BP at baseline and dose increases (hypertension risk)

Avoid:

  • Benzodiazepines (dependence risk, use only acute crisis <2-4 weeks)
  • Antipsychotics as monotherapy

⚠️ Warning: SSRI/SNRI may worsen anxiety initially. Advise patients to continue for 2 weeks before judging efficacy. Review suicidal ideation in first month, especially age <30 years.

Analysis Framework

Differential Diagnosis of Persistent Anxiety

ConditionDiscriminating Features
GADMultiple worry domains, persistent ≥6 months, no specific trigger
Panic DisorderDiscrete panic attacks, anticipatory anxiety about attacks
Social AnxietyFear limited to social/performance situations
OCDIntrusive thoughts + compulsive rituals
PTSDTrauma history, flashbacks, avoidance, hypervigilance
HyperthyroidismWeight loss, tremor, heat intolerance, ↑TSH
Substance misuseCaffeine >400mg/day, alcohol withdrawal, stimulant use

Treatment Selection Criteria

Patient with GAD (GAD-7 ≥5)
↓
Mild-moderate (GAD-7: 5-14) + patient preference?
↓
YES → Step 2: Low-intensity psychological intervention
      (Guided self-help, computerised CBT)
      Duration: 6-8 weeks
↓
NO or inadequate response
↓
Step 3: Choice of high-intensity intervention
↓
Patient preference + availability?
↓
Prefers psychological → CBT (16-20 sessions)
Prefers medication → SSRI (sertraline first-line)
Severe (GAD-7: 15-21) → Consider both CBT + SSRI
↓
Review at 12 weeks
↓
Inadequate response?
↓
YES → Switch SSRI or trial SNRI + consider Step 4 referral
NO → Continue, review every 8-12 weeks

Visual Aid

SSRI vs SNRI Selection

FactorSSRI (Sertraline)SNRI (Venlafaxine/Duloxetine)
LineFirst-lineSecond-line
EvidenceStrongest for GADReserve for SSRI failure
TolerabilityBetter (fewer discontinuation)More side effects
MonitoringNone requiredBP monitoring needed (venlafaxine)
ComorbidityDepression, panicChronic pain (duloxetine advantage)
CostLowerHigher

Key Points Summary

GAD-7 score ≥10 indicates need for treatment; score ≥15 suggests high-intensity intervention or specialist referral

Stepped care mandatory: Start Step 2 low-intensity psychological (guided self-help) before pharmacotherapy unless severe or patient preference

Sertraline first-line SSRI per NICE CG113; therapeutic trial requires 12 weeks at adequate dose before switching

Venlafaxine/duloxetine (SNRIs) reserved for SSRI failure/intolerance; venlafaxine requires BP monitoring at baseline and dose increases

Benzodiazepines avoided except acute crisis (<2-4 weeks); high dependence risk contradicts chronic GAD management

CBT gold standard psychological therapy: 16-20 sessions, equivalent efficacy to medication, preferred by many patients

Screen for comorbidities: 50-90% have depression (use PHQ-9); always assess suicide risk especially when initiating SSRI/SNRI age <30

📌 Remember: GAD requires 6+ months - shorter duration suggests adjustment disorder or acute stress reaction, altering management approach

Practice Questions: Generalised anxiety disorder

Test your understanding with these related questions

A 43-year-old woman presents with episodes of severe anxiety, palpitations, and sweating. These occur unpredictably and last 10-15 minutes. Between episodes she feels well. What is the most likely diagnosis?

1 of 5

Flashcards: Generalised anxiety disorder

1/10

What is the general management of opioid dependence? _____

TAP TO REVEAL ANSWER

What is the general management of opioid dependence? _____

Refer to drug services

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial